Anzeige
Mehr »
Login
Mittwoch, 08.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
Rio Tintos Muster: Erst die Investition, dann die Milliarden
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QGXF | ISIN: GB00BM8HZD43 | Ticker-Symbol: 63V
Frankfurt
08.01.25
09:15 Uhr
0,060 Euro
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
VERICI DX PLC Chart 1 Jahr
5-Tage-Chart
VERICI DX PLC 5-Tage-Chart

Aktueller Chart VERICI DX Aktie

Chart vergleichen mit:

Firmenname, WKN, ISIN oder Aktien-Kürzel

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%
Chart-Typ:
Zeitraum:
 
VERICI DX PLC-Investoren interessieren sich auch für diese Wertpapiere
Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciencesCANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up...
► Artikel lesen
Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPCSAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary...
► Artikel lesen
Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business HighlightsSAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary...
► Artikel lesen
Hoth Therapeutics, Inc.: Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin ToxicitiesHighlights: 100% of Patients in Cohort 1 Achieve Primary Efficacy Endpoint No Treatment-Related Adverse Effects Observed Preserves Cancer Treatment Efficacy...
► Artikel lesen
Hoth Therapeutics, Inc.: Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment StudyNEW YORK, Oct. 29, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company dedicated to developing new generation...
► Artikel lesen
Hoth Therapeutics, Inc.: Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now UnderwayNEW YORK, Oct. 15, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative treatments, is proud to announce the...
► Artikel lesen
Tempus AI, Inc.: Tempus Announces Four Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2024Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced four abstracts were accepted for presentation at the...
► Artikel lesen
Tempus AI Signs Real World Data Collaboration With BioNTech To Support Oncology PipelineBERLIN (dpa-AFX) - Tempus AI, Inc (TEM), a technology company using AI to advance precision medicine and patient care, Wednesday announced a multi-year real world data collaboration with BioNTech...
► Artikel lesen
Opening Bell: Coca-Cola, Visa, PayPal, Netflix, VF Corp, Philip Morris, Tempus AIDie kleine Zinseuphorie der letzten Woche ist an der Wall Street zum Wochenauftakt etwas in den Hintergrund gerückt. Der Dow Jones gab 0,16 Prozent ab. Der Nasdaq 100 verlor 1,04 Prozent. Bei den Einzelthemen...
► Artikel lesen